Please assess the completion status of the following clinical trial:

Trial Title: The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject is ≥7 years of age.~2. Subject has a clinical diagnosis of type 1 diabetes for more than 1 year as determined via medical records or source documentation by an individual qualified to make a medical diagnosis.~3. Subject has a HbA1c value greater than 6.5% and less than 12% at time of enrolment visit.~4. Subject is under Continuous Subcutaneous Insulin Infusion (CSII) therapy (with or without Continuous Glucose Monitoring) ≥ 6 months before enrolment.~5. Subject requires ≥8 units of insulin per day.~6. Subjects and their parent(s)/guardian(s) must be able to speak and be literate in French as verified by the investigator.~7. Subjects and their parent(s)/guardian(s) are willing to participate in the study and sign the Data Release Form (DRF).~8. Subjects who are ≥18 years of age should be able to provide consent.~Exclusion Criteria:~1. Subject has MiniMed™ 780G System IFU contraindication(s).~2. Subject uses Predictive Low-Glucose Management (PLGM) System (i.e. MiniMed™ 640G with SmartGuard) in the last 6 months before the enrolment.~3. Subject uses Low Glucose suspend (LGS) feature (i.e. MiniMed™ Paradigm Veo Pump) in the last 6 months before the enrolment.~4. Subject under Multiple-Daily Injections (MDI) treatment in the 6 months before the enrolment.~5. Subject has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- MiniMed™ 780G System (Type: None): Subject will use the MiniMed™ 780G System as per standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).